CA2391659A1 - Crystal forms of azithromycin - Google Patents

Crystal forms of azithromycin Download PDF

Info

Publication number
CA2391659A1
CA2391659A1 CA002391659A CA2391659A CA2391659A1 CA 2391659 A1 CA2391659 A1 CA 2391659A1 CA 002391659 A CA002391659 A CA 002391659A CA 2391659 A CA2391659 A CA 2391659A CA 2391659 A1 CA2391659 A1 CA 2391659A1
Authority
CA
Canada
Prior art keywords
azithromycin
crystal forms
infections
treatment
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002391659A
Other languages
French (fr)
Other versions
CA2391659C (en
Inventor
Zheng Jane Li
Andrew Vincent Trask
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2391659(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to CA002536501A priority Critical patent/CA2536501C/en
Priority to CA002500217A priority patent/CA2500217C/en
Priority to CA002536914A priority patent/CA2536914C/en
Publication of CA2391659A1 publication Critical patent/CA2391659A1/en
Application granted granted Critical
Publication of CA2391659C publication Critical patent/CA2391659C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections.
CA002391659A 2001-05-22 2002-05-01 Crystal forms of azithromycin Expired - Fee Related CA2391659C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002536501A CA2536501C (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin
CA002500217A CA2500217C (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin
CA002536914A CA2536914C (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US60/292,565 2001-05-22
US29774101P 2001-06-12 2001-06-12
US60/297,741 2001-06-12
US34304101P 2001-12-21 2001-12-21
US60/343,041 2001-12-21
PCT/IB2002/001570 WO2002094843A1 (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CA002536501A Division CA2536501C (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin
CA002536914A Division CA2536914C (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin
CA002500217A Division CA2500217C (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Publications (2)

Publication Number Publication Date
CA2391659A1 true CA2391659A1 (en) 2002-11-22
CA2391659C CA2391659C (en) 2006-05-30

Family

ID=27404135

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002391659A Expired - Fee Related CA2391659C (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Country Status (35)

Country Link
US (10) US6977243B2 (en)
EP (1) EP1390377B1 (en)
JP (3) JP2004530703A (en)
KR (1) KR100574153B1 (en)
AP (1) AP2003002906A0 (en)
AR (1) AR036022A1 (en)
AT (2) ATE404575T1 (en)
AU (1) AU2002256846B2 (en)
BG (1) BG108370A (en)
BR (1) BR0209918A (en)
CA (1) CA2391659C (en)
CR (1) CR7159A (en)
CZ (1) CZ20033154A3 (en)
DE (2) DE60228345D1 (en)
DK (1) DK1390377T3 (en)
EA (2) EA009611B1 (en)
EE (1) EE200300575A (en)
ES (2) ES2258142T3 (en)
GE (1) GEP20084399B (en)
HU (1) HUP0400446A2 (en)
IL (1) IL158591A0 (en)
IS (1) IS7007A (en)
MA (1) MA27023A1 (en)
MX (1) MXPA03010028A (en)
MY (1) MY129319A (en)
NO (2) NO321894B1 (en)
NZ (2) NZ529118A (en)
PA (1) PA8545701A1 (en)
PE (1) PE20021064A1 (en)
PL (1) PL367091A1 (en)
PT (1) PT1390377E (en)
SK (1) SK14402003A3 (en)
TN (1) TNSN03121A1 (en)
WO (1) WO2002094843A1 (en)
YU (1) YU91603A (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
CZ20011886A3 (en) * 1998-11-30 2001-10-17 Teva Pharmaceutical Industries Ltd. Azithromycin ethanolate, process of its preparation and pharmaceutical preparations containing thereof
EP1313749B1 (en) * 2000-08-23 2005-10-12 Wockhardt Limited Process for preparation of anhydrous azithromycin
KR100431431B1 (en) * 2001-04-25 2004-05-14 한미약품 주식회사 Clathrate of azithromycin hydrate with 1,2-propyleneglycol, methods for the manufacture thereof, and pharmaceutical compositions thereof
ATE404575T1 (en) * 2001-05-22 2008-08-15 Pfizer Prod Inc NEW CRYSTAL FORMS OF AZITHROMYCIN
ITMI20011762A1 (en) 2001-08-10 2003-02-10 Cosmo Spa 17ALPHA ESTERS, 21-DIHYDROXYPREGNENE, THEIR USE AS ANTI-ANDROGENETIC AGENTS AND PROCEDURES FOR THEIR PREPARATION
CA2469246A1 (en) 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
PL371125A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Methods for wet granulating azithromycin
EP1478347A1 (en) 2002-02-01 2004-11-24 Pfizer Products Inc. Dry granulated formulations of azithromycin
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
PL1648473T3 (en) * 2003-07-24 2009-07-31 Pliva Hrvatska D O O Single dose fast dissolving azithromycin
EP1878432A1 (en) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Single dose fast dissolving azithromycin
US7727987B2 (en) * 2003-11-17 2010-06-01 Merck Eprova Ag Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
EP1776365B1 (en) * 2004-06-02 2011-08-03 Sandoz Ag Meropenem intermediate in crystalline form
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
WO2007004230A2 (en) * 2005-07-05 2007-01-11 Hetero Drugs Limited A novel process for the preparation of didanosine using novel intermediates
WO2007007148A1 (en) * 2005-07-14 2007-01-18 Pfizer Products Inc. Process for forming amorphous azithromycin particles
EA018698B1 (en) * 2005-09-21 2013-10-30 4Сц Аг Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
NZ567357A (en) * 2005-10-31 2011-05-27 Janssen Pharmaceutica Nv Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
MX2008016008A (en) * 2006-06-16 2009-01-16 Lundbeck & Co As H Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain.
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
EP2615091B1 (en) * 2006-10-27 2016-01-20 Signal Pharmaceuticals, LLC Solid forms comprising 4-[9-(3S)-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-trans-cyclohexan-1-ol, compositions thereof, and uses therewith
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
ITMI20071616A1 (en) 2007-08-03 2009-02-04 Cosmo Spa ENZYMATIC PROCESS FOR THE OBTAINING OF 17-ALFA MONOESTERS OF CORTEXOLONE AND / OR ITS 9,11-DEIDRODERIVATI.
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (en) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag BENZHIDRIL ESTER OF THE ACID (6R, 7R) -7- {2- (5-AMINO- [1,2,4] TIADIAZOL-3-IL) -2 - [(Z) -TRITILOXIIMINO] -ACETILAMINO} -3- [ (R) -1'-TERC-BUTOXICARBONIL-2-OXO- [1,3 '] BIPIRROLIDINIL- (3E) -ILIDENOMETIL] -8-OXO-5-TIA-1-AZA-BICICLO [4.2.0] OCT- 2-ENO-2-CARBOXILICO CRISTALINO; YOUR ELABORATION AND USE
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
KR20120004448A (en) 2009-03-13 2012-01-12 다 볼떼라 Compositions and methods for elimination of gram-negative bacteria
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
ES2742195T3 (en) 2010-03-12 2020-02-13 Omeros Corp PDE10 inhibitors and related compositions and methods
CA2808904A1 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
US9174973B2 (en) * 2011-09-30 2015-11-03 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
CN107530313A (en) 2015-04-24 2018-01-02 奥默罗斯公司 PDE10 inhibitor and compositions related and method
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
CN111303230B (en) * 2020-03-09 2021-07-13 中国食品药品检定研究院 Progesterone eutectic compound and preparation method and application thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43116B (en) * 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) * 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
RU2066324C1 (en) * 1987-07-09 1996-09-10 Пфайзер Инк. Crystalline azithromycin dehydrate, and process for preparation thereof
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1034734C (en) 1993-12-10 1997-04-30 北京市集才药物研究所 Azierythromycin crystal and its preparation method
CN1093370A (en) * 1993-12-10 1994-10-12 北京市集才药物研究所 A kind of new azido erythromycin crystal and preparation method thereof
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DK0915899T3 (en) * 1996-07-29 2004-11-29 Abbott Lab Preparation of crystalline form II of clarithromycin
CN1161971A (en) 1997-01-03 1997-10-15 石家庄制药集团有限公司 Azimycin crystal and preparation method thereof
PT102130A (en) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A METHOD FOR PREPARING AZITHROMYCY DIHYDRATE
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (en) * 1998-09-09 2003-08-19 한미약품공업 주식회사 Method for preparing Form 2 of clarithromycin without residual solvent
CZ20011886A3 (en) * 1998-11-30 2001-10-17 Teva Pharmaceutical Industries Ltd. Azithromycin ethanolate, process of its preparation and pharmaceutical preparations containing thereof
WO2001000640A1 (en) * 1999-06-29 2001-01-04 Biochemie S.A. Macrolides
ES2177373B1 (en) 1999-11-26 2003-11-01 Astur Pharma Sa PREPARATION OF AZITHROMYCIN IN ITS NON-CRYSTALLINE FORM
CA2396426A1 (en) * 2000-01-04 2001-07-12 Teva Pharmaceutical Industries Ltd. Preparation method of azithromycin dihydrate
ES2162764B1 (en) 2000-05-17 2003-04-01 Ercros Ind Sa POLYMORPHIC FORM OF AZITHROMYCIN DIHYDRATE, AND ITS DEOBTENTION PROCEDURE.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
WO2002010144A1 (en) * 2000-07-25 2002-02-07 Laboratorio Silanes, S.A. De C.V. Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-ona and obtaining a new form of 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
ES2172417B1 (en) 2000-07-31 2003-09-16 Sint Quimica Sa NEW IMPROVED FORM OF AZITROMYCIN MONOHIDRATE OF LOW HYGROSCOPICITY, PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT.
ITBO20000471A1 (en) 2000-07-31 2002-01-31 Vieri Ridolfi SUPPORT DEVICE FOR SMOKE PRODUCTS PARTICULARLY CIGARETTES.
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
EP1313749B1 (en) 2000-08-23 2005-10-12 Wockhardt Limited Process for preparation of anhydrous azithromycin
HU229488B1 (en) 2000-11-27 2014-01-28 Sandoz Ag Process for the preparation of macrolide hydrates
IN190080B (en) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (en) 2001-04-25 2004-05-14 한미약품 주식회사 Clathrate of azithromycin hydrate with 1,2-propyleneglycol, methods for the manufacture thereof, and pharmaceutical compositions thereof
ATE404575T1 (en) * 2001-05-22 2008-08-15 Pfizer Prod Inc NEW CRYSTAL FORMS OF AZITHROMYCIN
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ES2324527T3 (en) 2001-10-18 2009-08-10 Teva Pharmaceutical Industries Ltd. STABILIZED AZITHROMYCIN COMPOSITIONS.

Also Published As

Publication number Publication date
EA200301115A1 (en) 2004-04-29
US6977243B2 (en) 2005-12-20
PA8545701A1 (en) 2003-09-05
US20050192234A1 (en) 2005-09-01
EA200500630A1 (en) 2006-02-24
NO321894B1 (en) 2006-07-17
DE60209704D1 (en) 2006-05-04
BR0209918A (en) 2004-03-30
JP4584162B2 (en) 2010-11-17
US20040082527A1 (en) 2004-04-29
PL367091A1 (en) 2005-02-21
PE20021064A1 (en) 2002-11-21
CA2391659C (en) 2006-05-30
US20030162730A1 (en) 2003-08-28
NZ539801A (en) 2006-10-27
KR20040014525A (en) 2004-02-14
ATE319730T1 (en) 2006-03-15
US20050256063A1 (en) 2005-11-17
MY129319A (en) 2007-03-30
ES2258142T3 (en) 2006-08-16
GEP20084399B (en) 2008-06-10
ES2310886T3 (en) 2009-01-16
NO20035177D0 (en) 2003-11-21
US20050090459A1 (en) 2005-04-28
EP1390377B1 (en) 2006-03-08
MA27023A1 (en) 2004-12-20
JP2004530703A (en) 2004-10-07
KR100574153B1 (en) 2006-04-25
US20050245469A1 (en) 2005-11-03
US20050256062A1 (en) 2005-11-17
ATE404575T1 (en) 2008-08-15
CR7159A (en) 2004-02-23
NZ529118A (en) 2005-10-28
US20040138149A1 (en) 2004-07-15
NO20061049L (en) 2003-05-12
JP2006152002A (en) 2006-06-15
YU91603A (en) 2006-08-17
EP1390377A1 (en) 2004-02-25
TNSN03121A1 (en) 2005-12-23
US7081525B2 (en) 2006-07-25
IL158591A0 (en) 2004-05-12
MXPA03010028A (en) 2004-02-12
JP2007161726A (en) 2007-06-28
PT1390377E (en) 2006-06-30
BG108370A (en) 2004-11-30
EE200300575A (en) 2004-04-15
US7309782B2 (en) 2007-12-18
US7053192B2 (en) 2006-05-30
AR036022A1 (en) 2004-08-04
DE60228345D1 (en) 2008-09-25
US20040043944A1 (en) 2004-03-04
US20040043945A1 (en) 2004-03-04
IS7007A (en) 2003-10-30
WO2002094843A1 (en) 2002-11-28
HUP0400446A2 (en) 2004-09-28
EA007618B1 (en) 2006-12-29
SK14402003A3 (en) 2004-06-08
US7282486B2 (en) 2007-10-16
US7105179B2 (en) 2006-09-12
CZ20033154A3 (en) 2004-04-14
DK1390377T3 (en) 2006-06-19
AU2002256846B2 (en) 2007-04-05
DE60209704T2 (en) 2006-11-16
US7307156B2 (en) 2007-12-11
AP2003002906A0 (en) 2003-12-31
EA009611B1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
CA2391659A1 (en) Crystal forms of azithromycin
GB0125222D0 (en) Composition for the treatment of microbial infections
WO2003088897A3 (en) Fab i inhibitors
MXPA03003168A (en) Topical antibiotic composition for treatment of eye infection.
AU2003245928A1 (en) Antibacterial amide macrocycles
CA2470809A1 (en) 6-amino-morphinan derivatives, method of manufacturing them and their application
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
CA2536501A1 (en) Crystal forms of azithromycin
AU2001258675A1 (en) Treating infections
ECSP034861A (en) CRYSTALLINE FORMS OF AZITHROMYCIN
AU2002242096A1 (en) Novel compounds and methods for inhibiting/treating hiv infections and aids related symptoms
AU2003263978A1 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
WO2002057281A3 (en) Aminoglycosides as antibiotics
AU2002349533A1 (en) Antimicrobial glass and process for producing the same
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2003285599A1 (en) Novel semisynthetic macrolide antibiotics of the azalide series
AU2002303480A1 (en) Glycopeptide antibiotics
MX342808B (en) Glycopeptide antibiotics.
AUPR967401A0 (en) Treatment of bacterial infections
AU2001281657A1 (en) Therapeutic process for p. aeruginosa infections using macrolide antibiotics
AU2002324798A1 (en) Pyrazolo-pyridines for the treatment of herpes infections
AU2002303498A1 (en) Antibiotics aa-896
AU2002251251A1 (en) Oxazolidinone-sulfoximines and -sulfilimines as antibiotics
AU2000226913A1 (en) Novel antibiotic wk-6150 and process for producing the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130501